Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top ...

A judge has denied Tallahassee City Commissioner Jeremy Matlow's request to have his lawsuit against the Blueprint Intergovernmental Agency board reheard. Circuit Judge John Cooper threw out ...

Shop 2001 Cadillac DeVille vehicles in Clarksville, TN for sale at Cars.com. Research, compare, and save listings, or contact sellers directly from 3 2001 DeVille models in Clarksville, TN.

Cadillac Lyric recall number: Owners can contact Cadillac at 1-800-333-4223. The number for this recall is N252500680. Owners may also contact the NHTSA Vehicle Safety Hotline at 1-888-327-4236 or ...

Shop Cadillac DeVille vehicles in Chelsea, MA for sale at Cars.com. Research, compare, and save listings, or contact sellers directly from 134 DeVille models in Chelsea, MA.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline The deal is Sanofi’s third acquisition so far this year, and executives signaled that more acquisitions could follow By ...

Is Tesla's EV dominance being challenged? Discover how Cadillac's growing electric lineup is successfully attracting buyers who previously owned Teslas, shifting the luxury EV landscape.

The Blueprint deal comes after Sanofi made an unsuccessful play in 2022 for another rare disease specialist, Horizon Therapeutics. In that case, Amgen took the prize with its $27.8 billion offer.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...